A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. [electronic resource]
Producer: 20170623Description: 784-8 p. digitalISSN:- 1532-1827
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Disease-Free Survival
- Docetaxel
- Drug Resistance, Neoplasm
- Drug Substitution
- Dyspnea -- chemically induced
- Fatigue -- chemically induced
- Female
- Gastrointestinal Diseases -- chemically induced
- Greece
- Hematologic Diseases -- chemically induced
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Taxoids -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.